Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
Want to see ZBIO full AI Analyst Report?
Total Valuation
Zenas BioPharma, Inc. has a market cap or net worth of $1.16B. The enterprise value is $672.93M.
Market Cap$1.16B
Enterprise Value$672.93M
Share Statistics
Zenas BioPharma, Inc. has 63,133,377 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63,133,377
Owned by Insiders25.17%
Owned by Institutions47.33%
Financial Efficiency
Zenas BioPharma, Inc.’s return on equity (ROE) is -1.56 and return on invested capital (ROIC) is -65.61%.
Return on Equity (ROE)-1.56
Return on Assets (ROA)-0.98
Return on Invested Capital (ROIC)-65.61%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee76.92K
Profits Per Employee-2.91M
Employee Count130
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Zenas BioPharma, Inc. is ―. Zenas BioPharma, Inc.’s PEG ratio is -0.03.
PE Ratio―
PS Ratio162.41
PB Ratio6.71
Price to Fair Value6.71
Price to FCF-9.42
Price to Operating Cash Flow-4.86
PEG Ratio-0.03
Income Statement
In the last 12 months, Zenas BioPharma, Inc. had revenue of 10.00M and earned -377.74M in profits. Earnings per share was -8.44.
Revenue10.00M
Gross Profit10.00M
Operating Income-211.38M
Pretax Income-377.82M
Net Income-377.74M
EBITDA-370.43M
Earnings Per Share (EPS)-8.44
Cash Flow
In the last 12 months, operating cash flow was -210.48M and capital expenditures -2.00K, giving a free cash flow of -210.48M billion.
Operating Cash Flow-210.48M
Free Cash Flow-210.48M
Free Cash Flow per Share-3.33
Dividends & Yields
Zenas BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.56
52-Week Price Change82.90%
50-Day Moving Average20.01
200-Day Moving Average24.58
Relative Strength Index (RSI)45.26
Average Volume (3m)523.89K
Important Dates
Zenas BioPharma, Inc. upcoming earnings date is Aug 18, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Zenas BioPharma, Inc. as a current ratio of 5.61, with Debt / Equity ratio of 104.73%
Current Ratio5.61
Quick Ratio5.61
Debt to Market Cap0.05
Net Debt to EBITDA0.08
Interest Coverage Ratio-28.85
Taxes
In the past 12 months, Zenas BioPharma, Inc. has paid -79.00K in taxes.
Income Tax-79.00K
Effective Tax Rate<0.01
Enterprise Valuation
Zenas BioPharma, Inc. EV to EBITDA ratio is -4.30, with an EV/FCF ratio of -9.25.
EV to Sales159.35
EV to EBITDA-4.30
EV to Free Cash Flow-9.25
EV to Operating Cash Flow-9.25
Balance Sheet
Zenas BioPharma, Inc. has $717.21M in cash and marketable securities with $351.73M in debt, giving a net cash position of $365.48M billion.
Cash & Marketable Securities$717.21M
Total Debt$351.73M
Net Cash$365.48M
Net Cash Per Share$5.79
Tangible Book Value Per Share$5.41
Margins
Gross margin is 0.00%, with operating margin of -2113.85%, and net profit margin of -3777.37%.
Gross Margin0.00%
Operating Margin-2113.85%
Pretax Margin-3778.16%
Net Profit Margin-3777.37%
EBITDA Margin-3704.33%
EBIT Margin-3704.89%
Analyst Forecast
The average price target for Zenas BioPharma, Inc. is $43.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.67
Price Target Upside100.12% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast-128.73%